Subscribe
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Archive

Indian government approves FabiFlu for mild to moderate COVID-19 patients.- Glenmark Pharma

Written by | 23 Jun 2020

Glenmark Pharmaceuticals announced the launch of antiviral drug FabiFlu (favipiravir) for the treatment of mild to moderate COVID-19 patients. Glenmark has received manufacturing and marketing approval from India’s… read more.

Ridgeback Biotherapeutics announces the launch of two phase II clinical trials to test the efficacy of EIDD 2801 as an anti-viral treatment for COVID-19.Merck Inc.

Written by | 21 Jun 2020

Ridgeback Biotherapeutics announces the launch of two Phase II clinical trials to test the efficacy of EIDD 2801 as an anti-viral treatment for COVID-19. Phase I trials recently… read more.

Low-cost dexamethasone reduces death by up to one third in hospitalised patients with severe respiratory complications of COVID-19.- Generic

Written by | 18 Jun 2020

In March 2020, the RECOVERY (Randomised Evaluation of COVid-19 thERapY) trial was established as a randomised clinical trial to test a range of potential treatments for COVID-19, including… read more.

Is indomethacin a better choice than ibuprofen in covid-19?

Written by | 17 Jun 2020

Interview and article by Christine Clark. Compared with ibuprofen, indomethacin has additional beneficial actions, argues Dr Rajan Ravichandran Commenting on the LIBERATE* study (NCT04334629) that is now in… read more.

Indomethacin to combat cytokine release syndrome in covid-19

Written by | 17 Jun 2020

Interview and article by Christine Clark. Dr Rajan Ravichandran’s experience of using indomethacin to control cytokine release syndrome led him to realise that it could also be useful… read more.

Indomethacin – dual antiviral and anti-inflammatory for covid-19?

Written by | 17 Jun 2020

Interview and article by Christine Clark. Indomethacin has both anti-inflammatory and anti-viral properties and it could help to hasten recovery from covid-19 infection Indomethacin, if given early to… read more.

Soleno Therapeutics announces top-line results from phase III trial of DCCR for treatment of Prader-Willi syndrome.

Written by | 14 Jun 2020

Soleno Therapeutics, Inc. announced top-line results from the Company’s Phase III trial, DESTINY PWS (C601), evaluating once-daily Diazoxide Choline Controlled Release (DCCR) tablets for patients with Prader-Willi Syndrome… read more.

Johnson & Johnson initiates Phase I/IIa trial of Ad26.COV2-S, recombinant, to treat COVID-19.

Written by | 12 Jun 2020

Johnson & Johnson announced that through its Janssen Pharmaceutical Companies (Janssen) it has accelerated the initiation of the Phase 1/IIa first-in-human clinical trial of its investigational SARS-CoV-2 vaccine,… read more.

Johnson & Johnson initiates Phase I/IIa trial of Ad26.COV2-S, recombinant, to treat COVID-19.

Written by | 12 Jun 2020

Johnson & Johnson announced that through its Janssen Pharmaceutical Companies (Janssen) it has accelerated the initiation of the Phase 1/IIa first-in-human clinical trial of its investigational SARS-CoV-2 vaccine,… read more.

Fulcrum Therapeutics to evaluate losmapimod in Phase III trial as a potential treatment for COVID-19.

Written by | 11 Jun 2020

Fulcrum Therapeutics, Inc. announced plans to evaluate losmapimod as a potential treatment for patients with COVID-19 . Fulcrum has submitted an investigational new drug (IND) application to support… read more.

Gilead Sciences files MAA for remdesivir at the EMA to treat COVID-19.

Written by | 9 Jun 2020

The European Medicines Agency (EMA) reports that Gilead Sciences has submitted its marketing application seeking conditional approval of antiviral remdesivir for the treatment of COVID-19. Since the EU… read more.

CE Mark for OPTI SARS-CoV-2 RT-PCR laboratory test kit for the detection of SARS-CoV-2,.- Opti Medical Systems

Written by | 9 Jun 2020

OPTI Medical Systems, Inc., a subsidiary of IDEXX Laboratories, Inc. announced that it has received the CE mark certification in the European Union for its OPTI SARS-CoV-2 RT-PCR… read more.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.

Subscribe

You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.